Opinion: The FDA’s absence from international standards meetings threatens U.S. leadership

What's new in pharma

August 15, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jose Luis Magana/AP STAT+ | Opinion: The FDA's absence from international standards meetings threatens U.S. leadership It is absolutely essential that the U.S. government ensure FDA staff are present at international standards meetings. By Naomi Schwartz and Axel Wirth STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Vinay Prasad's return, animal testing alternatives, and mRNA upended On this week's episode of "The Readout Loud," the hosts discuss the sudden return of Prasad at the FDA and the mixed prospects for mRNA. By Allison DeAngelis and Elaine Chen Molly Ferguson for STAT STAT+ | Layers of political oversight have 'put sand in the gears' of NIH grant funding How Trump and DOGE reshaped the NIH: delayed funds, canceled projects, and scientists scrambling to save research as billions in grants stall By Anil Oza, Megan Molteni, and Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser